Search results
Lexington 16-year-old student wins $75,000 for what could be a medical breakthrough
Lexington Herald-Leader via Yahoo News· 3 days agoA medical device to diagnose and treat health problems earns a 16-year-old junior from Lexington’s...
Finding Undiagnosed Asthma, COPD and Treating It Shows Benefit in Trial
MedPage Today· 3 days agoIdentifying symptomatic individuals in the community with undiagnosed asthma and chronic obstructive...
Risks for Hydroxychloroquine Retinopathy Described in Detail
Medscape· 23 hours agoOlder patients prescribed hydroxychloroquine (HCQ) have a higher risk of developing retinal damage from taking the medication, according to a new analysis. In addition to known risk factors ...
Perseus Therapeutics Announces Development of TSLP Antibody for Prevention of Hair Loss in Cancer...
WKBN 27 Youngstown· 11 hours agoPerseus Therapeutics, a pioneering biopharmaceutical company based in New York City, is proud to announce the development of a novel thymic stromal lymphopoietin (TSLP) antibody aimed at preventing ...
On the Move: May 16, 2024
Nashville Post· 7 days agoHarrow, ThriveAP, Titan Cloud announce updates
Beyond Wegovy, the Search Is On for Muscle-Saving Obesity Drugs
Bloomberg· 6 days agoHave a confidential tip for our reporters? Now drugmakers are rushing to solve another problem —...
Once-Promising Drug for Idiopathic Pulmonary Fibrosis Fails in Phase III Trial
MedPage Today· 3 days agoThe fully human monoclonal antibody pamrevlumab failed to improve lung function among patients with...
FDA approves 2 Eylea biosimilars
Becker’s Hospital Review· 3 days agoThe FDA granted approval to Biocon Biologics' drug Yesafili and Samsung Bioepis and Biogen's drug Opuviz, the agency announced May 20. The two drugs are biosimilars for Eylea, an injection made ...
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S....
WTRF Wheeling· 2 days agoBiocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration ...
J&J hooks Proteologix for $850M cash, reeling in a roster of early bispecifics
FierceBiotech· 7 days agoJohnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of...